Development and characterization of an anti-rituximab monoclonal antibody panel

During the development of monoclonal antibodies (mAbs) and other therapeutic proteins, immunogenicity, in particular the induction of anti-drug antibodies (ADAs), is an important concern, and thus immunogenicity assessment is a requirement for their approval. Establishment of appropriate methods for...

Descripción completa

Detalles Bibliográficos
Autores principales: Tada, Minoru, Suzuki, Takuo, Ishii-Watabe, Akiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916554/
https://www.ncbi.nlm.nih.gov/pubmed/29309213
http://dx.doi.org/10.1080/19420862.2018.1424610

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916554/
https://www.ncbi.nlm.nih.gov/pubmed/29309213
http://dx.doi.org/10.1080/19420862.2018.1424610

Ejemplares similares